Skip to content

Independent medical information for international patients

Menu

Disease

Pancreatic cancer胰腺癌

ICD-10: C25 — Malignant neoplasm of pancreas

Group: Cancer Specialty: General Surgery, Hepatobiliary Surgery, Medical Oncology

Key figures

Published values only. Every tile opens the section that carries its source, its year and its caliber.

Disease details

Standard Chinese name
胰腺癌
English name
Malignant neoplasm of pancreas

Values written in Chinese are quoted as published by the source.

Also known as

  • Pancreatic carcinoma
  • Pancreatic ductal adenocarcinoma

Treatment cost ranges

Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.

Treatment path Cost range Price basis Data year
Surgery 手术 90000 – 90000 CNY Condition package price 病种打包全包价 2020
Surgery 手术 85000 – 85000 CNY Condition package price 病种打包全包价 2020

The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 90000 CNY. Each row keeps its own data year and caliber.

2 cost ranges for this condition, each with its source on the row page.

Values written in Chinese are quoted as published by the source.

See all cost ranges →

Five-year survival

5-year survival rate 8.5% 95% CI 8.2–8.7

Population
Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
Period
2019–2021
Publisher
National Cancer Center 国家癌症中心
Value nature
Estimated value (hybrid analysis) 估计值（混合法）
Registry scope
281 population-based cancer registries 281 个肿瘤登记处
Stage data availability
Not published

Values written in Chinese are quoted as published by the source.

See all survival rates →

How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.

The figure is relative survival: it compares people diagnosed with this cancer against people of the same age and sex in the general population, and it is age-standardised, so it is not the share of patients still alive after five years. It is published as an estimated value (hybrid analysis) because registry reports arrive with a lag, so the National Cancer Center modelled the most recent period. For context, the same source publishes 43.7% five-year relative survival for all cancers combined in 2019–2021.

Hospitals with a published record for this condition

Selected using official public data sources

These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.

How these hospitals were selected

Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.

Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.

Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.

When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.

The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.

  1. Cancer Hospital of Chinese Academy of Medical Sciences中国医学科学院肿瘤医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Research platform

    Also ranked: Thoracic Surgery #1, Urology nominated in the Fudan list.

  2. Peking Union Medical College Hospital中国医学科学院北京协和医院

    Dongcheng District 东城区

    Fudan specialty reputation ranking 2023

    Also ranked: Urology #8, Gynecology #1, Otorhinolaryngology #4 in the Fudan list.

  3. Zhongshan Hospital复旦大学附属中山医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: Thoracic Surgery #6, Gastroenterology #9, Respiratory Medicine #6 in the Fudan list.

  4. Sun Yat-sen University Cancer Center中山大学肿瘤防治中心

    Guangzhou 广州市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: Thoracic Surgery #9 in the Fudan list.

  5. West China Hospital, Sichuan University四川大学华西医院

    Chengdu 成都市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: Thoracic Surgery #4, Urology #2 (tied), Otorhinolaryngology #8 in the Fudan list.

  6. Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: Thoracic Surgery #10, Nuclear Medicine 核医学 nominated in the Fudan list.

  7. Ruijin Hospital上海交通大学医学院附属瑞金医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: Thoracic Surgery #7 (tied), Respiratory Medicine #5, Infectious Diseases 传染感染 #6 in the Fudan list.

  8. Peking University Cancer Hospital北京大学肿瘤医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: Nuclear Medicine 核医学 nominated in the Fudan list.

Clinical trials (investigational treatments)

In addition to standard care, clinical research studies for Pancreatic cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.

  1. Study Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine As Postoperative Adjuvant Therapy in Patients with EGFR-positive Pancreatic Cancer: a Prospective, Single-arm Study

    Hospital
    Zhejiang Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT06722911

  2. Study Nab-Paclitaxel/Gemcitabine Followed by mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Previously Untreated Advanced Pancreatic Cancer: A Randomized, Controlled, Multicenter Phase III Trial

    Lead investigator
    Ying Jieer · Director of Department
    Hospital
    Zhejiang Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07235930

  3. Study Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial

    Lead investigator
    Jinbo Yue · Jinbo Yue
    Hospital
    Shandong Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06050317

  4. Study Efficacy and Safety of Nano-Megestrol Acetate in the Treatment of Anorexia-Cachexia Syndrome in Patients With Advanced Pancreatic Cancer: A Randomized, Controlled, Prospective Study

    Lead investigator
    Jinbo Yue · Director of Radiation Oncology Department
    Hospital
    Shandong Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07408505

  5. Study Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) -A Single-Arm Phase Ib/II Trial

    Lead investigator
    Jinbo Yue · Director of Department Radiation Oncology
    Hospital
    Shandong Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06844422
39 more registered studies

  1. Study A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

    Hospital
    Peking Union Medical College Hospital
    Status
    Recruiting
    Registry
    NCT07678593

  2. Study A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer

    Hospital
    Tianjin Medical University Cancer Institute & Hospital
    Status
    Recruiting
    Registry
    NCT06760364

  3. Study A Prospective Single-center Observational Study: ctDNA-guided Maintenance Therapy for Postoperative Pancreatic Cancer

    Lead investigator
    Du Juan · Chief Physician
    Hospital
    Nanjing Drum Tower Hospital
    Status
    Recruiting
    Registry
    NCT07054879

  4. Study Adjuvant Chemoradiotherapy Versus Chemotherapy for Post-operative Pancreatic Cancer

    Lead investigator
    Zhang Huo Jun
    Status
    Recruiting
    Registry
    NCT06427447

  5. Study Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer

    Lead investigator
    Guo ShiWei
    Status
    Recruiting
    Registry
    NCT04743479

  6. Study A Multicenter, Open-label, Phase II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Combination With Chemotherapy as First-line Treatment in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

    Hospital
    Peking Union Medical College Hospital
    Status
    Recruiting
    Registry
    NCT05859750

  7. Study A Prospective Cohort Study on the Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer: A Comprehensive Analysis Based on Multidimensional Dynamic Psychological Assessment (MIND-PANC)

    Hospital
    Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT07529626

  8. Study The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.

    Lead investigator
    Hu Jiajia · Deputy director
    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT06601010

  9. Study An Open-label, Single-arm, Multicenter, Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of CT041 Autologous CAR T Cell Injection After Adjuvant Chemotherapy in Subjects With Pancreatic Cancer

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT05911217

  10. Study A Prospective, Single-Center, Phase II Clinical Study of Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen (Liposomal Irinotecan, Oxaliplatin, and S-1) Hepatic Arterial Infusion Chemotherapy (HAIC) and Intra-Arterial Programmed Death-1 (PD-1) Inhibitors for Liver Metastases From Pancreatic Cancer

    Lead investigator
    Zhongmin Wang · Principal Investigator
    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT07504471

  11. Study a Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial of HRS-4642 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as First-Line Therapy in Patients With Advanced or Metastatic Pancreatic Carcinoma Harboring KRAS G12D Gene Mutation

    Hospital
    Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Status
    Recruiting
    Registry
    NCT07232875

  12. Study Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study

    Hospital
    Ningbo Medical Center Lihuili Hospital
    Status
    Recruiting
    Registry
    NCT07542002

  13. Study Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients

    Hospital
    Henan Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT06375473

  14. Study A Multicenter Study Assessing the Efficacy and Safety of Icaritin in Combination With AG Chemotherapy Versus AG Chemotherapy Alone in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma

    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Recruiting
    Registry
    NCT06825546

  15. Study An Open-label, Single-center, Single-arm Study to Evaluate the Efficacy and Safety of Low-dose Radiation Therapy Combined With Pultelimab and Standard Treatment in Patients With Advanced Pancreatic Cancer

    Lead investigator
    Liu Yang · MD
    Hospital
    Zhejiang Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT07312422

  16. Study A Phase II Trial to Evaluate the Efficacy of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Pancreatic Tumors

    Hospital
    Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
    Status
    Recruiting
    Registry
    NCT07006077

  17. Study A Phase 1/2, Open-label, Biomarker-guided, Dose-escalation and Expansion Study of Dual-targeting CAR-NK Cells Directed Against Mesothelin (MSLN) and MUC1, With an Exploratory CLDN18.2/MUC1 Dual-target Cohort, in Patients With Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

    Hospital
    Peking University Shenzhen Hospital
    Status
    Recruiting
    Registry
    NCT07627711

  18. Study A Multicenter, Randomized, Open-label, Active-controlled, Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine Versus Nab-paclitaxel Plus Gemcitabine as the First-line Treatment in Metastatic Pancreatic Cancer

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT06361888

  19. Study Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety

    Lead investigator
    Jiang Long · Chief physician of hepatobiliary and pancreatic surgery
    Hospital
    Shanghai General Hospital
    Status
    Recruiting
    Registry
    NCT06531278

  20. Study A Proof of Concept Study of Pancreatic Cancer Early Detection by cfDNA Assay

    Lead investigator
    Xian-Jun Yu · Principal Investigator
    Hospital
    Fudan University Shanghai Cancer Center
    Status
    Recruiting
    Registry
    NCT06166147

  21. Study Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis

    Lead investigator
    Jiang Long · Chief physician of hepatobiliary and pancreatic surgery
    Hospital
    Shanghai General Hospital
    Status
    Recruiting
    Registry
    NCT06307080

  22. Study Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.

    Lead investigator
    Li Tian, MD · Li Tian, MD [fu3tianli]
    Hospital
    Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT06655233

  23. Study A Single-arm, Exploratory Clinical Study of Trilaciclib Combined With mFOLFIRINOX Regimen in the Treatment of Patients With Advanced Pancreatic Cancer

    Hospital
    Nanjing Drum Tower Hospital
    Status
    Recruiting
    Registry
    NCT06151262

  24. Study Clinical Trial Evaluating the Safety and Activity of Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

    Lead investigator
    Guo ShiWei
    Status
    Recruiting
    Registry
    NCT04146298

  25. Study A Randomized, Double-blind, Parallel-controlled, Multicenter Phase III Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules to Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07165951

  26. Study A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data

    Hospital
    Zhongshan Hospital
    Status
    Recruiting
    Registry
    NCT07561814

  27. Study An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer

    Hospital
    Zhongshan Hospital
    Status
    Recruiting
    Registry
    NCT06938282

  28. Study An Exploratory Clinical Study of HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

    Lead investigator
    BAIYONG SHEN · Professor
    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT06587061

  29. Study Clinical Study of Personalized Tumor Vaccines mRNA-0217/S001 and Pabolizumab in Patients With Advanced Pancreatic Cancer

    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT05916261

  30. Study Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer: a Prospective, Randomized Controlled Clinical Trial

    Lead investigator
    Dai, Guanghai · Professor
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT05218889

  31. Study A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer

    Lead investigator
    YiHui Guan · Professor
    Hospital
    Huashan Hospital
    Status
    Recruiting
    Registry
    NCT07707531

  32. Study A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.

    Lead investigator
    Dan Sha · Chief Physician
    Hospital
    Shandong Provincial Hospital
    Status
    Not yet recruiting
    Registry
    NCT07333287

  33. Study A Multicenter, Single-arm, Prospective Study of SBRT Combined With Zimberelimab (GLS-010) in Patients With Locally Advanced Pancreatic Cancer (SPARK-1 Study)

    Hospital
    Peking University Third Hospital
    Status
    Not yet recruiting
    Registry
    NCT06009029

  34. Study Human Chimeric Antigen Receptor Macrophages Targeting C-MET for C-MET-positive Advanced Stage of Pancreatic Cancer Patients: A Single-arm, Single-center, IIT Study

    Hospital
    Peking Union Medical College Hospital
    Status
    Not yet recruiting
    Registry
    NCT07553793

  35. Study Efficacy and Safety of XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer Patients

    Hospital
    Peking Union Medical College Hospital
    Status
    Not yet recruiting
    Registry
    NCT07114666

  36. Study Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: An Open-Label, Single-Arm, Phase II Study

    Lead investigator
    Fan Wang · Associate Chief Physician
    Hospital
    Shanghai General Hospital
    Status
    Not yet recruiting
    Registry
    NCT07733050

  37. Study A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer

    Hospital
    Xiangya Hospital of Central South University
    Status
    Not yet recruiting
    Registry
    NCT07231094

  38. Study Immune Repertoire Decoding Enables Dynamic Risk Stratification During Chronic Pancreatitis-to-Pancreatic Cancer Transition

    Lead investigator
    Zhuan Liao
    Status
    Not yet recruiting
    Registry
    NCT07762950

  39. Study The Efficacy and Safety of Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer: A Prospective, Single Arm, Phase II Clinical Study

    Hospital
    Zhongshan Hospital
    Status
    Not yet recruiting
    Registry
    NCT06166589

This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.

Advanced therapies: what is licensed and what is in trials

Hospitals with a national key specialty record

Show the hospital records 66 hospitals with a key-specialty record

Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.

Hospital City Specialty (as published) Evidence Source
Renji Hospital, Shanghai Jiao Tong University School of Medicine上海交通大学医学院附属仁济医院
Tier 3 · HIGHEST
 Shanghai 上海市 General Surgery 普外科 Level B https://www.renji.com/gh/article/list/01/01
XinHua Hospital上海交通大学医学院附属新华医院
Tier 3 · HIGHEST
 Shanghai 上海市 General Surgery 普外科 Level B https://www.xinhuamed.com.cn/?channel=hot
Ruijin Hospital上海交通大学医学院附属瑞金医院
Tier 3 · HIGHEST
 Shanghai 上海市 General Surgery 普外科 · Medical Oncology 肿瘤中心 Level B https://www.rjh.com.cn/2018RJPortal/lcyxy2019/sy/jj/index.shtml
https://www.rjh.com.cn/2018rjportal/rjzlk/ksjs/index.shtml
Shanghai General Hospital上海市第一人民医院
Tier 3 · HIGHEST
 Shanghai 上海市 General Surgery 普外临床医学中心 · Medical Oncology 肿瘤中心 Level B https://www.firsthospital.cn/List/Depart/f0
Shanghai Pulmonary Hospital上海市肺科医院
Tier 3 · HIGHEST
 Shanghai 上海市 Medical Oncology 肿瘤科 Level B https://www.shsfkyy.com/gzb/list/b980f2cf4b134e5d85397ced965ce260/74344ed2746449a68d71c2b76c8cf423.html
Zhongshan Hospital复旦大学附属中山医院
Tier 3 · HIGHEST
 Shanghai 上海市 General Surgery 普通外科 Level B https://www.zs-hospital.sh.cn/zhuanye/content/5140.html
Huashan Hospital复旦大学附属华山医院
Tier 3 · HIGHEST
 Shanghai 上海市 Medical Oncology 肿瘤科 Level B https://www.huashan.org.cn/yygk/hsyyjs.htm
Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院
Tier 3 · HIGHEST
 Shanghai 上海市 Medical Oncology 肿瘤科 · Hepatobiliary Surgery 胰腺肿瘤 Level B https://www.shca.org.cn/home/news/content/id/297/pid/25651
Cancer Hospital of Chinese Academy of Medical Sciences中国医学科学院肿瘤医院 Beijing 北京市 Medical Oncology 肿瘤科 Level B https://www.cicams.ac.cn/news/401.html
China-Japan Friendship Hospital中日友好医院 Beijing 北京市 Medical Oncology 中西医结合肿瘤内科 · Hepatobiliary Surgery 普外科（肝胆外科） Level B https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
Beijing Hospital北京医院
Tier 3 · HIGHEST
 Beijing 北京市 General Surgery 普通外科 Level B https://www.bjhmoh.cn/index.php?id=4&r=archives/about&t=1790009033
Peking University People's Hospital北京大学人民医院 Beijing 北京市 General Surgery 普外科 · Medical Oncology 肿瘤科 · Medical Oncology 骨肿瘤科 Level B https://www.pkuph.cn/news_details/26715.html
Peking University First Hospital北京大学第一医院 Beijing 北京市 General Surgery 普通外科 Level B https://www.pkufh.com/Html/News/Articles/64494.html
Peking University Third Hospital北京大学第三医院 Beijing 北京市 General Surgery 普通外科 Level B https://www.puh3.net.cn/yygk/zdxk.htm
Peking University Cancer Hospital北京大学肿瘤医院 Beijing 北京市 Medical Oncology 肿瘤科 Level B https://www.bjcancer.org/Html/Hospitals/Main/Description.html
Xuanwu Hospital of Capital Medical University首都医科大学宣武医院
Tier 3 · HIGHEST
 Beijing 北京市 Medical Oncology 肿瘤科 Level A https://ygch.ccmu.edu.cn/lcxkjz/xkpt/gjlczdzk/index.htm
Beijing Friendship Hospital, Capital Medical University首都医科大学附属北京友谊医院
Tier 3 · HIGHEST
 Beijing 北京市 General Surgery 普通外科 Level A https://ygch.ccmu.edu.cn/lcxkjz/xkpt/gjlczdzk/index.htm
Beijing Tiantan Hospital, Capital Medical University首都医科大学附属北京天坛医院 Beijing 北京市 Medical Oncology 神经肿瘤科 Level A https://ygch.ccmu.edu.cn/lcxkjz/xkpt/gjlczdzk/index.htm
West China Hospital, Sichuan University四川大学华西医院
Tier 3 · HIGHEST
 Chengdu 成都市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital四川省医学科学院·四川省人民医院
Tier 3 · HIGHEST
 Chengdu 成都市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://www.samsph.com/news_hos/2023/xe7kw1e7.html
https://www.samsph.com/introduce/
Sichuan Cancer Hospital四川省肿瘤医院
Tier 3 · HIGHEST
 Chengdu 成都市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://www.sichuancancer.org/yygk/yyjs.htm
Tianjin Medical University General Hospital天津医科大学总医院
Tier 3 · HIGHEST
 Tianjin 天津市 General Surgery 普通外科 Level B https://www.tjmugh.com.cn/system/2019/01/02/020008655.shtml
Tianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院 Tianjin 天津市 Medical Oncology 肿瘤学 Level B https://www.tjmuch.com/yygk/yyjj/index_yg.shtml
Anhui Provincial Hospital中国科学技术大学附属第一医院（安徽省立医院） Hefei 合肥市 General Surgery 普外科 · Medical Oncology 肿瘤科 Level B https://www.ahslyy.com.cn/nanqu/col456/892156
The First Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院 Hefei 合肥市 General Surgery 普外科 · Medical Oncology 肿瘤科 Level B https://www.ayfy.com/info/1184/27750.htm
The Second Hospital of Shandong University山东大学第二医院
Tier 3 · HIGHEST
 Jinan 济南市 General Surgery 普通外科 Level A https://file.byfy.cn/Resource/File/Upload/file/20251203/20251203160857_1590.pdf
Qilu Hospital of Shandong University山东大学齐鲁医院
Tier 3 · HIGHEST
 Jinan 济南市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level A Level B https://www.qiluhospital.com/index.php?m=content&c=index&a=show&catid=681&id=33049
http://wsjkw.shandong.gov.cn/zwgk/fdzdgknr/gsgg/202406/t20240613_4736124.html
Shandong Provincial Qianfoshan Hospital山东省千佛山医院 Jinan 济南市 General Surgery 普通外科 Level A https://file.byfy.cn/Resource/File/Upload/file/20251203/20251203160857_1590.pdf
Shandong Provincial Hospital山东省立医院
Tier 3 · HIGHEST
 Jinan 济南市 General Surgery 普通外科 Level A http://wsjkw.shandong.gov.cn/zwgk/fdzdgknr/gsgg/202406/t20240613_4736124.html
Shandong Cancer Hospital山东省肿瘤医院 Jinan 济南市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level A http://wsjkw.shandong.gov.cn/zwgk/fdzdgknr/gsgg/202406/t20240613_4736124.html
http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Sun Yat-sen Memorial Hospital, Sun Yat-sen University中山大学孙逸仙纪念医院 Guangzhou 广州市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://www.gzsys.org.cn/basic/453
Sun Yat-sen University Cancer Center中山大学肿瘤防治中心 Guangzhou 广州市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://www.sysucc.org.cn/node/8565
The First Affiliated Hospital, Sun Yat-sen University中山大学附属第一医院 Guangzhou 广州市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://gcp.fahsysu.org.cn/sites/1h.gcp.sysucloud1.sysu.edu.cn/files/2023-07/20230625%20中山大学附属第一医院宣传折页%20V5.0_0.pdf
The Third Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院 Guangzhou 广州市 General Surgery 普通外科 Level B https://www.zssy.com.cn/basic/468
Nanfang Hospital南方医科大学南方医院 Guangzhou 广州市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://www.nfyy.com/index.html
Guangdong Provincial People's Hospital广东省人民医院 Guangzhou 广州市 General Surgery 普外科 · Medical Oncology 肿瘤科 · Hepatobiliary Surgery 胰腺中心 Level B https://www.gdghospital.org.cn/newshospital/info_itemid_32986.html
https://static.nfnews.com/content/202503/22/c11108498.html
https://www.gdghospital.org.cn/NewsHospital/info_itemid_67669.html
First Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院
Tier 3 · HIGHEST
 Guangzhou 广州市 Medical Oncology 肿瘤科 Level B https://www.gyfyy.com/cn/job/a_108951.html
Nanjing Drum Tower Hospital南京鼓楼医院（南京大学医学院附属鼓楼医院）
Tier 3 · HIGHEST
 Nanjing 南京市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://www.njglyy.com/zbmz/zbmz2.aspx
https://med.nju.edu.cn/2e/be/c10655a208574/page.htm
Jiangsu Province Hospital江苏省人民医院（南京医科大学第一附属医院）
Tier 3 · HIGHEST
 Nanjing 南京市 Hepatobiliary Surgery 肝胆外科 Level B https://www.jsph.org.cn/info/3031/71721.htm
Jiangsu Cancer Hospital江苏省肿瘤医院
Tier 3 · HIGHEST
 Nanjing 南京市 Medical Oncology 肿瘤科 Level B https://www.jszlyy.com.cn/home/news/content/id/476/pid/47579
Henan Provincial People's Hospital河南省人民医院 Zhengzhou 郑州市 General Surgery 普通外科专业 Level C Not published
Henan Cancer Hospital河南省肿瘤医院 Zhengzhou 郑州市 General Surgery 普外科 · Medical Oncology 肿瘤科 Level B https://anti-cancer.com.cn/Mobile/Journal/ArticleIndex/2171
https://www.anti-cancer.com.cn/Html/Hospitals/Main/Description.html
First Affiliated Hospital of Zhengzhou University郑州大学第一附属医院 Zhengzhou 郑州市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://www.zdyfy.cn/tsyl/gjjlczdzk
The First Affiliated Hospital, Zhejiang University School of Medicine浙江大学医学院附属第一医院
Tier 3 · HIGHEST
 Hangzhou 杭州市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level A http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
The Second Affiliated Hospital Zhejiang University School of Medicine浙江大学医学院附属第二医院
Tier 3 · HIGHEST
 Hangzhou 杭州市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level A http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine浙江大学医学院附属邵逸夫医院
Tier 3 · HIGHEST
 Hangzhou 杭州市 General Surgery 普通外科学 Level A http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
Zhejiang Provincial People's Hospital浙江省人民医院
Tier 3 · HIGHEST
 Hangzhou 杭州市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://hospitalstar.com/#/intro/courtyard?id=1&cid=204&fnav=2
Zhejiang Cancer Hospital浙江省肿瘤医院
Tier 3 · HIGHEST
 Hangzhou 杭州市 Medical Oncology 肿瘤科 Level B https://www.zchospital.com/cn/article/98
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology华中科技大学同济医学院附属协和医院 Wuhan 武汉市 General Surgery 普外科 · Medical Oncology 肿瘤科 Level B https://www.whuh.com/kxyj/xkjs/gjlczdzk/2.htm
https://www.whuh.com/kxyj/xkjs/gjlczdzk.htm
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院
Tier 3 · HIGHEST
 Wuhan 武汉市 Medical Oncology 儿童血液与肿瘤科 · General Surgery 普通外科：甲乳外科 · Hepatobiliary Surgery 普通外科：肝脏外科 · Hepatobiliary Surgery 普通外科：胆胰外科 · Medical Oncology 肿瘤科 Level B https://www.tjh.com.cn/contents/934/27291.html
Zhongnan Hospital of Wuhan University武汉大学中南医院 Wuhan 武汉市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://www.znhospital.com/Uploads/Picture/2025/03/06/u67c8f245cacb9.pdf
Hubei Cancer Hospital湖北省肿瘤医院 Wuhan 武汉市 Medical Oncology 肿瘤科 Level B https://www.hbch.com.cn/category/1-11.html
Third Xiangya Hospital中南大学湘雅三医院
Tier 3 · HIGHEST
 Changsha 长沙市 General Surgery 普通外科 Level B https://www.xy3yy.com/ksjj/184173.html
Second Xiangya Hospital of Central South University中南大学湘雅二医院 Changsha 长沙市 General Surgery 普通外科 Level B https://www.xyeyy.com/655/656/664/
Xiangya Hospital of Central South University中南大学湘雅医院
Tier 3 · HIGHEST
 Changsha 长沙市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://www.xiangya.com.cn/zdzk.html
Hunan Provincial People's Hospital湖南省人民医院
Tier 3 · HIGHEST
 Changsha 长沙市 Hepatobiliary Surgery 肝胆外科（肝胆医院） Level B http://www.hnsrmyy.com/index.php?catid=115
Hunan Cancer Hospital湖南省肿瘤医院
Tier 3 · HIGHEST
 Changsha 长沙市 Medical Oncology 肿瘤科 Level B https://hnca.org.cn/wap/zdks/
Shengjing Hospital中国医科大学附属盛京医院
Tier 3 · HIGHEST
 Shenyang 沈阳市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://www.sj-hospital.cn/article/82.html
https://www.sj-hospital.cn/article/84.html
First Hospital of China Medical University中国医科大学附属第一医院
Tier 3 · HIGHEST
 Shenyang 沈阳市 Hepatobiliary Surgery 器官移植科/肝胆外科 · General Surgery 普通外科 · Medical Oncology 肿瘤内科 Level B https://www.cmu1h.com/features/specialty
Liaoning Cancer Hospital辽宁省肿瘤医院
Tier 3 · HIGHEST
 Shenyang 沈阳市 Medical Oncology 肿瘤学 · Medical Oncology 肿瘤科 Level A Level B https://www.lnchi.org.cn/ch/hospital/biref/index.html
https://wsjk.ln.gov.cn/wsjk/index/gsgg/D6FB5218203A456D9540155A2D928D84/index.shtml
The First Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院 Chongqing 重庆市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://www.hospital-cqmu.com/gzb/yygk/yyjj.htm
The Second Affiliated Hospital of Chongqing Medical University重庆医科大学附属第二医院 Chongqing 重庆市 General Surgery 普通外科 Level A https://wsjkw.cq.gov.cn/zwgk_242/fdzdgknr/tzgg/gzgs/202412/t20241225_14021980_wap.html
Chongqing University Cancer Hospital重庆大学附属肿瘤医院 Chongqing 重庆市 Medical Oncology 肿瘤科 Level B https://www.cqch.cn/sitemap
Chongqing General Hospital重庆市人民医院 Chongqing 重庆市 General Surgery 普通外科 Level B https://www.cghhospital.org/into_hos
The First Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院
Tier 3 · HIGHEST
 Xi'an 西安市 General Surgery 普通外科 · Medical Oncology 肿瘤科 Level B https://news.xjtu.edu.cn/info/1033/17951.htm
The Second Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院
Tier 3 · HIGHEST
 Xi'an 西安市 Medical Oncology 肿瘤科 Level B http://2yuan.xjtu.edu.cn/defsyy/xwzx1/yyyw_/4.htm

66 hospitals with a matching national key specialty record.

Values written in Chinese are quoted as published by the source.

What patients report

Aggregate figures only: a national result quoted with its source and the year it refers to. This is not a patient testimonial and not a statement about one person.

  • As reported in National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023): National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.

    National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).

    Source: National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Level A

All therapy & access topics

Questions about this condition

We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.

Ask us about this condition

ICD codes

Show the code table 1 ICD code
Version Code Name in that version
ICD-10-WHO C25 Malignant neoplasm of pancreas

Rows are the WHO ICD-10 entries for this condition, quoted as published.

Source & evidence

Source URL
https://qzybj.quanzhou.gov.cn/qt/gzcx/bzsfcx/202006/P020221216571645625406.pdf
Source scheme
https
Source type
Provincial health commission
Evidence level
A - stated by a health commission, a national research institute or a university
Retrieved on
2026-09-30